Narrow search
Showing 1 - 10 of 107
Cover Image
Pharmaceutical innovation, longevity, and medical expenditure in Greece, 1995 - 2010
Lichtenberg, Frank - 2015
death), hospital utilization, and medical expenditure in Greece during the period 1995 - 2010. The estimates indicate that … increases in the number of hospital days. Real per capita pharmaceutical expenditure increased rapidly during this period, but … 62% of the increase in pharmaceutical expenditure was offset by a reduction in hospital expenditure attributable to …
Persistent link: https://www.econbiz.de/10010473542
Cover Image
The impact of pharmaceutical innovation on longevity and medical expenditure in Sweden, 1997-2010 : evidence from longitudinal, disease-level data
Lichtenberg, Frank R.; Pettersson, Billie - 2012
the number of drugs to treat a disease, not the number of drug classes. Pharmaceutical innovation also reduced hospital …
Persistent link: https://www.econbiz.de/10009571756
Cover Image
The benefits and costs of newer drugs : evidence from the 1996 medical expenditure panel survey
Lichtenberg, Frank R. - 2000
The nation's spending for prescription drugs has grown dramatically in recent years. Previous studies have shown that the replacement of older drugs by newer, more expensive, drugs is the single most important reason for this increase, but they did not measure how much of the difference between...
Persistent link: https://www.econbiz.de/10011397709
Cover Image
Margins and market shares : pharmacy incentives for generic substitution
Brekke, Kurt R.; Holmås, Tor Helge; Straume, Odd Rune - 2012
generics and their market shares. This relationship is stronger for pharmaceuticals under reference pricing rather than …. -- pharmaceuticals ; pharmacies ; generic substitution …
Persistent link: https://www.econbiz.de/10009691207
Cover Image
Reference pricing, competition, and pharmaceutical expenditures : theory and evidence from a natural experiment
Brekke, Kurt R.; Holmås, Tor Helge; Straume, Odd Rune - 2010
-savings, and that patients' copayments decrease despite the extra surcharges under RP. -- pharmaceuticals ; regulation ; generic …
Persistent link: https://www.econbiz.de/10008749029
Cover Image
Choosing among competing blockbusters : does the identity of the third-party payer matter for prescribing doctors?
Dalen, Dag Morten; Sorisio, Enrico; Strøm, Steinar - 2010
are price responsive, and that the price response is considerably higher when the doctor's affiliated hospital covers the … treatment instead of insurance the total cost of treatment is significantly reduced. -- pharmaceuticals ; discrete choice model …
Persistent link: https://www.econbiz.de/10008699739
Cover Image
Pricing the pharmaceuticals when the ability to pay differs : taking vertical equity seriously
Kanniainen, Vesa; Laine, Juha; Linnosmaa, Ismo - 2019
A non-trivial fraction of people cannot afford to buy pharmaceutical products at unregulated market prices. Therefore, the paper analyzes the public insurance of the pharmaceutical products in terms of price controls and the socially optimal third-degree price discrimination. It characterizes...
Persistent link: https://www.econbiz.de/10012157261
Cover Image
Moral hazard in drug purchases
Verho, Jouko; Harju, Jarkko - 2023
We study the moral hazard effects of the drug copayment threshold in Finland using detailed prescription drug purchase data. The analysis reveals that the average drug costs increase discontinuously by 17% at the threshold above which out-of-pocket drug costs decrease substantially. Our results...
Persistent link: https://www.econbiz.de/10014289803
Cover Image
A probability approach to pharmaceutical demand and price setting : does the identity of the third-party payer matters for prescribing doctors?
Dalen, Dag Morten; Locatelli Biey, Marilena; Sorisio, Enrico - 2011
national insurance. -- pharmaceuticals ; discrete choice model ; funding-schemes …
Persistent link: https://www.econbiz.de/10009377790
Cover Image
Is medicines parallel trade "regulatory arbitrage"?
Costa-Font, Joan - 2015
In the European Union, medicines are regulated products subject to both single market (e.g., regional exhaustion of property rights) and country specific health care regulations (e.g., medicines pricing). This gives rise to parallel trade (PT), a phenomenon that takes place when a patented...
Persistent link: https://www.econbiz.de/10010477153